Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.56 |
| ▸ | NOS1 | P29475 | 3/20 | 0.56 |
| ▸ | NOS2 | P35228 | 3/20 | 0.56 |
| ▸ | DPP4 | P27487 | 3/20 | 0.54 |
| ▸ | FAP | Q12884 | 2/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030783 | 1.00 | NOS3 (0.56) | NOS3NOS1NOS2DPP4FAP | |
| SCHEMBL42646 | 1.00 | NOS3 (0.56) | NOS3NOS1NOS2DPP4FAP | |
| SCHEMBL29429685 | 1.00 | NOS3 (0.56) | NOS3NOS1NOS2DPP4FAP | |
| Hydrochloric Acid SCHEMBL25215525 | 0.98 | NOS3 (0.55) | NOS3NOS1NOS2DPP4FAP | |
| SCHEMBL25718868 | 0.85 | DPP4 (0.53) | NOS3NOS1NOS2DPP4FAP | |
| SCHEMBL28346433 | 0.84 | KMT2A (0.53) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL28710330 | 0.83 | NOS3 (0.56) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL28710331 | 0.83 | NOS3 (0.56) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL7382769 | 0.83 | CYP1A2 (0.50) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL10067850 | 0.82 | NOS3 (0.49) | NOS3NOS1NOS2DPP4FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-12 | — | — | US | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| WO-2025094171-A1 | SUPERHYDROPHOBIC COATING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-05-08 | — | — | WO | claimed |
| EP-4401555-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-07-24 | — | — | EP | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| WO-2023042201-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-23 | — | — | WO | claimed |
| US-20150368480-A1 | ANTIFOULING MATERIALS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-12-24 | — | — | US | claimed |
| EP-2951195-A1 | ANTIFOULING MATERIALS | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2015-12-09 | — | — | EP | claimed |
| WO-2014118779-A1 | ANTIFOULING MATERIALS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-08-07 | — | — | WO | claimed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | claimed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | NOS3 379/4885NOS1 454/4885NOS2 252/4885 |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | NOS3 3751/4885NOS1 3043/4885NOS2 3668/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | NOS3 3324/4885NOS1 2043/4885NOS2 3210/4885 |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, TPX2 | NOS3 4508/4885NOS1 4533/4885NOS2 4575/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | NOS3 1894/4885NOS1 2308/4885NOS2 2092/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | NOS3 1235/4885NOS1 828/4885NOS2 1000/4885 |
| US-20150368480-A1 | ANTIFOULING MATERIALS | PFAS, FLNB, FLNA | NOS3 486/4885NOS1 714/4885NOS2 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.